Methods of treatment of spontaneous preterm birth

Patent metadata

Field	Value
Publication number	US-12310934-B2
Application number	US-202017440178-A
Country	US
Kind code	B2
Filing date	Mar 20, 2020
Priority date	Mar 20, 2019
Publication date	May 27, 2025
Grant date	May 27, 2025

Abstract

Spontaneous preterm birth (sPTB) is premature delivery prior to 37 weeks of pregnancy and is a leading cause of infant mortality worldwide. sPTB is associated with a unique gene expression profile. Identified herein are numerous safe and proven therapeutic compositions used for unrelated indications that have the biological effect of reversing, in part, the gene expression profile of sPTB and which can be used in preventative or interventional treatments to prevent, delay, or ameliorate sPTB. The repurposed drugs include several Class A and Class B therapeutics that are regarded as safe or low risk in pregnant subjects.

First claim

The invention claimed is:

1. A method of treating spontaneous preterm birth in a subject in need of treatment therefor by the administration to the subject of a therapeutic composition comprising a therapeutically effective amount of one or more agents that partially reverse the gene expression profile associated with spontaneous preterm birth.

2. The method of claim 1 , wherein the subject is a subject at any stage of pregnancy.

3. The method of claim 1 , wherein the subject is a subject having one or more risk factors or symptoms of spontaneous preterm birth.

4. The method of claim 1 , wherein the treatment is a preventative treatment.

5. The method of claim 1 , wherein the therapeutic composition comprises an agent that partially reverses the gene expression profile associated with spontaneous preterm birth selected from the group consisting of: naproxen, cefotaxime, levopropoxyphene, prednisone, vorinostat, brompheniramine, genistein, valproic acid, cefoperazone, alprostadil, lansoprazole, iopamidol, letrozole, molindone, fluticasone, estradiol, isoxicam, thiamphenicol, guanabenz, isometheptene, isoniazid, sulfadimethoxine, ribavirin, pioglitazone, benzocaine, pentoxifylline, meclofenamic acid, rosiglitazone, methotrexate, domperidone, amitriptyline, vinblastine, naringenin, fulvestrant, sodium phenylbutyrate, haloperidol, zalcitabine, zuclopenthixol, iohexol, adenosine phosphate, iodixanol, viomycin, nimodipine, ciclosporin, rifabutin, podophyllotoxin, ceforanide, sirolimus, ajmaline, diloxanide, chlortalidone, trimethobenzamide, timolol, tenoxicam, ketotifen, geldanamycin, dantrolene, dapsone, streptozocin, raloxifene, ambroxol, benzathine benzylpenicillin, finasteride, trifluoperazine, vanoxerine, thiamazole, homosalate, levomepromazine, co-dergocrine mesilate, oxyphenbutazone, promazine, carisoprodol, niclosamide, methoxamine, tocainide, cefotiam, maprotiline, resveratrol, and nadolol.

6. The method of claim 5 , wherein the therapeutic composition comprises lansoprazole.

7. The method of claim 5 , wherein the therapeutic composition comprises cefotaxime.

8. The method of claim 5 , wherein the therapeutic composition comprises rifabutin.

9. The method of claim 5 , wherein the therapeutic composition comprises chlortalidone.

10. The method of claim 5 , wherein the therapeutic composition comprises benzathine benzylpenicillin.

11. The method of claim 5 , wherein the therapeutic composition comprises maprotiline.

12. The method of claim 5 , wherein the therapeutic composition comprises naproxen.

Assignees

• Univ California
• The Leland Stanford Junior Univ
• Univ Leland Stanford Junior

Inventors

• Sirota Marina
• Le Brian
• Wong Ronald
• Stevenson David

Classifications

• A61K31/192 Primary

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• A61K31/573

  substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title

• A61K31/546

  containing further heterocyclic rings, e.g. cephalothin · CPC title

• A61K31/4439

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61K31/4402

  only substituted in position 2, e.g. pheniramine, bisacodyl · CPC title